Imipramine Remedica

Imipramine Hydrochloride, the active ingredient in Imipramine Remedica, is a tricyclic antidepressant presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients, helping to alleviate depressive symptoms by modulating neurotransmitter levels.

GNH USA supplies Imipramine Remedica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent product quality across global markets.

Imipramine Remedica, a tricyclic antidepressant, is used primarily in the management of depressive disorders.

- Major depressive disorder: alleviates depressive symptoms by increasing synaptic norepinephrine and serotonin. - Panic disorder: reduces frequency and severity of panic attacks through central nervous system modulation. - Nocturnal enuresis (children): decreases nighttime urinary episodes by influencing bladder control mechanisms.

Imipramine may cause a range of adverse reactions, from mild to serious. Awareness of these effects supports safe monitoring.

Common Side Effects: - Dry mouth: reduced salivary flow causing discomfort. - Constipation: slowed gastrointestinal motility. - Blurred vision: transient visual disturbances. - Drowsiness or fatigue: increased sedation. - Weight gain: gradual increase in body weight. - Orthostatic hypotension: dizziness upon standing.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, especially in patients with pre‑existing heart disease. - Seizures: heightened risk in susceptible individuals. - Severe hypotension: sudden drop in blood pressure. - Suicidal ideation: emergence or worsening of suicidal thoughts. - Blood dyscrasias: rare hematologic abnormalities such as agranulocytosis. - Hepatotoxicity: liver enzyme elevations or injury.

Before initiating therapy, clinicians should consider several safety measures.

- Cardiac assessment: obtain baseline ECG in patients with cardiac risk factors. - Dose titration: start low and increase gradually to minimize side effects. - Concomitant CNS depressants: avoid or monitor use with alcohol, benzodiazepines, or opioids. - Elderly patients: use reduced doses and monitor for anticholinergic effects. - Pregnancy and lactation: evaluate risk‑benefit ratio as safety data are limited. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Imipramine interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome. - Selective serotonin reuptake inhibitors (SSRIs) or other serotonergic agents: potential serotonin syndrome. - Drugs that prolong QT interval: increased risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise imipramine plasma levels. - Antihistamines and anticholinergics: additive anticholinergic burden. - Alcohol: enhances sedation and orthostatic hypotension. - CNS depressants: may increase drowsiness and impair psychomotor performance.